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Role of the -adducin genotype on renal disease progression. in patients suffering from renal diseases. Genes that di-
Background. A genetic susceptibility to hypertension may pre- rectly or indirectly regulate renal sodium reabsorption
dispose to the development of end-stage renal disease (ESRD) may be extremely important in patients with nephropa-and promote a more rapid loss of renal function in patients
thies.with renal diseases. The -adducin (ADD) gene, alone or in
Among the proteins that may indirectly affect renalcombination with the angiotensinogen (AGT) and the angio-
tensin-converting enzyme (ACE), is a candidate for abnormal sodium handling the cytoskeleton protein adducin is of
blood pressure regulation and thus for increased susceptibility particular interest. Adducin is a heterodimeric protein that
or faster progression to ESRD. consists of, and  subunits [6]. It promotes the bindingMethods. Genotyping for the G460W-ADD, M235T-AGT
of spectrin with actin and also directly binds actin andand the insertion/deletion (I/D)-ACE gene polymorphisms was
bundles actin filaments [6, 7]. Its role is believed to beperformed in 260 control subjects and 260 ESRD patients using
polymerase chain reaction, gel analysis and appropriate restric- the regulation of the assembly of spectrin and actin [6].
tion digest. As a consequence adducin can modulate the structure
Results. The frequencies of the ADD, AGT and ACE geno-
of the cytoskeleton and the exposure of transmembranetypes in ESRD patients did not differ from observed frequen-
proteins. It has been demonstrated that the actin-basedcies in control subjects. The average (SE) time from diagnosis
to the onset of ESRD tended to be shorter in the presence of cytoskeleton interacts with the epithelial Na channel [8],
the ADD-460WW (5.1  1.1 years, N  10) than with the GW the Na-K-Cl cotransporter [9] and Na,K-ATPase [10].
(9.9  0.7 years, N  81) and GG (11.3  1.0 years, N  164) Bianchi et al recently identified a polymorphism within
genotypes (F-ratio2.71, P  0.068; WW vs. GW P  0.06 and
the -adducin gene that is associated with hypertensionvs. GG 0.03). In the 167 patients homozygous for the ADD-G
in Milan hypertensive strain rats and in hypertensiveallele, a more rapid progression with the ACE-DD genotype as
compared to ACE-DI and II was found (P  0.02). patients [11, 12]. This association has been confirmed in
Conclusions. The ADD genotype is predictive of the course other Caucasian [13] and Japanese populations by some
of renal function loss in an unselected renal population and laboratories [14]; however, other groups were unable toinfluences the effect of the ACE genotype to modulate the
reproduce these findings [15, 16]. The different -adducinrate of progression to ESRD. Thus, the ADD genotype may
isoforms differentially affect the Na,K-ATPase activityplay a role for the understanding of interindividual differences
in the course of renal diseases. on the basolateral tubular membrane, which is the driv-
ing force of overall tubular Na reabsorption [17]. This
may explain why the patients with “hypertensive” (460Trp)
Nephropathies of any etiology tend to progress to end- -adducin alleles are salt sensitive [12], have a less steep
stage renal disease (ESRD) [1], hypertension being one pressure natriuresis relationship [18], have an increased
of the major contributors in the progression of renal proximal tubular Na reabsorption [18], and have a larger
failure [2]. The prevalence of hypertension increases with blood pressure (BP) fall after diuretic treatment and
decreasing renal function [3]. Moreover, hypertension lower plasma renin activity (PRA) [12] when compared
per se is a risk factor for the development of ESRD with patients homozygous for the wild-type (Gly460) ad-
[4, 5]. It is possible that a genetic predisposition to hyper- ducin allele. Thus, the -adducin (ADD) glycine to tryp-
tension may contribute to the development of renal fail- tophan (G460W) polymorhism alone or in combination
ure and/or promote a more rapid loss of renal function with elements of the renin-angiotensin system (RAS)
could play a role in the susceptibility and progression of
renal diseases to ESRD. Among the possible RAS genes,Key words: genetics, hypertension, kidney, end-stage renal disease,
adducin, renin-angiotensin system. the angiotensinogen (AGT) polymorphism 235T allele is
associated with hypertension and increased angiotensino-Received for publication August 3, 2001
gen levels [19] and with a susceptibility for ESRD in dia-and in revised form November 6, 2001
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Table 1. Baseline demographic characteristics of the 520 subjects studied, subdivided by population groups
Control subjects (N260) ESRD patients (N260)
Healthy Hypertension Dialysis Transplantation
N 135 125 102 158
Sex M/F 78/57 68/57 59/43 89/69
Age years 4815 5917b 6413b 4812c
BMI kg/m2 23.63.5 27.45.5b 25.04.3a 24.94.6a
Blood pressure mm Hg
Systolic 12815 15421b 15026b 13714bc
Diastolic 789 9114b 8115 868bc
Data are mean  SD.
a P  0.01, b P  0.0001 vs. healthy controls
c P  0.0001 vs. dialysis patients
verting enzyme (ACE) insertion/deletion (I/D) polymor- time when serum creatinine increased120mol/L until
the time of onset of ESRD.phism the D allele is associated with higher plasma ACE
Genetic analysis for the G460W-ADD, M235T-AGTlevels [21] and a faster progression to ESRD [20].
and D/I-ACE genotypes was performed in all 520 sub-Thus, the aim of the present study was twofold: first,
jects and the prevalence of identified polymorphisms wasto test whether the ADD polymorphism affects the rela-
analyzed in patients with ESRD as compared to controltionship between genotype and onset/progression of
subjects for susceptibility to renal diseases and withinESRD; and second, to evaluate a possible synergistic
the ESRD population for the progression of renal func-interaction between adducin polymorphism and AGT
tion loss.or ACE polymorphisms in renal patients.
DNA preparation, PCR analysis and genotyping
METHODS Genomic DNA was isolated from peripheral blood and
detection of polymorphisms was performed by polymer-Subjects
ase chain reaction (PCR) analysis as previously describedStudy subjects were 260 white patients with ESRD
[20]. Polymorphism detection for the M235T-AGT and(either dialysis or transplanted) from our Division of
I/D-ACE genes was performed with the primers, condi-Nephrology and Hypertension, University Hospital of
tions and when appropriate by restriction typing of PCRBerne, Switzerland and 260 white control subjects with-
products as previously described [20]. The G460W-ADDout renal diseases (Table 1). Basic demographic data, in-
polymorphism was analyzed by PCR amplification of ge-cluding current blood pressure (BP), information on as-
nomic DNA followed by restriction digest as described
sociated diseases and current medication, including the
by Bray et al [22]. Genomic DNA (100 ng) was amplified
type and number of antihypertensive drugs was obtained using the forward primer 5	-CTCCTTTGCTAGTGAC
for all subjects. In the control group serum creatinine GGTGATTC-3	 and, to introduce a Sau96I restriction
was104 mol/L, proteinuria30 mg/L and urinary sedi- site, the mismatched reverse primer 5	-GACTTGGGA
ment was normal in all subjects. For ESRD patients the CTGCTTCCATTCGGCC-3	, in a total volume of 50L
date of diagnosis of the renal disease, renal histology, containing 20 pmol of each primer, 200 mol/L of each
time of onset of ESRD, type of renal replacement treat- deoxynucleotide triphosphate, and 0.5 U AmpliTaqGold
ment, age at transplantation, BP in the pre-ESRD period polymerase. Amplification was carried out under the
and other information were also available. Subjects ad- following conditions: one cycle of four minutes at 95
,
mitted to our service with serum creatinine150mol/L 40 cycles of 60 seconds at 95
, 60 seconds at 57
, and 60
(1.7 mg/dL) and whose renal history could not be re- seconds at 72
, followed by five minutes at 72
 and five
trieved were excluded. The time from diagnosis of the minutes at 98
. Amplified products were digested with
renal disease to the onset of ESRD was used a measure Sau96I at 37
 for two hours [22]. All PCR products were
for progression. Subgroup analysis by diagnosis of renal analyzed on 12% acrylamide gels containing 7.25% glyc-
disease was performed for the following etiologies: glo- erol using a two-buffer system. Four microliters of the
merulonephritis (N 76), interstitial nephritis (N 40), PCR sample were loaded and DNA was visualized by
diabetes mellitus (N 32), autosomal dominant polycys- silver staining [20].
tic kidney disease (N  30), pyelonephritis or vesicoure-
Statisticsteral reflux (N 25), nephroangiosclerosis (N 14), and
others (N  40). In patients with autosomal dominant Values are expressed as mean SD or percent. Statis-
tical differences between means were assessed by t testpolycystic kidney disease progression was defined as the
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Table 3. Comparison of biallelic frequencies in percent alone andTable 2. Comparison of allelic frequencies in percent among
controls and ESRD patients combined among controls and ESRD patients
Controls ESRDADD AGT ACE
Cases N W T D
ADD
GG 67.3 64.2Controls 520 18.1 41.3 49.4
Normal 270 15.9 39.2 48.5 WW 3.5 3.8
AGTHypertension 250 20.4 43.6 50.4
ESRD 520 19.8 42.5 45.6 MM 34.6 30.8
TT 17.7 15.8Dialysis 204 18.1 42.7 42.2
Transplanted 316 20.9 42.4 47.8 ACE
II 20.9 24.3
DD 20.5 15.8
AGT/ACE
MM/II 6.9 8.1
TT/DD 4.2 1.5or ANOVA for analysis of continuous variables and by
AGT/ADDnon-parametric analysis using the Wilcoxon or Kruskal-
MM/GG 23.1 21.5
Wallis test for variables that were not normally distrib- TT/WW 1.1 1.1
ACE/ADDuted. For categorical variables the 2  2 contingency
II/GG 14.6 16.1table 2 test was used. The expected “disease” frequency
DD/WW 1.1 0.8
for the target population was calculated according to the
Biallelic pairs are shown for the combinations that are supposed to protectHardy-Weinberg Equation [23]. All statistical analyses against or predispose to high blood pressure. For instance, since the AGT-M235T
allele has been associated with high angiotensinogen levels and the ACE-DDwere performed using the Systat 9.0 (SPSS Inc., Chicago,
variant was found to have higher plasma ACE activity, a combination of bothIL, USA) statistical software package. (AGT-TT  ACE-DD) would more likely be associated with hypertension and
ESRD than the mirror combination (AGT-MM  ACE-II).
RESULTS
Baseline demographic data of the subjects investigated
with GW (N  83) or GG (N  167) alleles (ANOVAin the present study are outlined in Table 1 and are sub-
F-ratio  2.71, P  0.068, WW vs. GW P  0.06 anddivided by the different population subgroups. Allele fre-
vs. GG 0.03 by t test, Fig. 1). The rate of progressionquencies in controls and ESRD patients stratified by
of renal disease tended to be shorter in patients with thesubgroups for the ADD, AGT and ACE genes are re-
W allele (9.4  8.2 years) as compared to patients withported in Table 2. In the ESRD group at the time of
the GG genotype (11.3  7.8 years, P  0.074). Whendiagnosis patients were comparable for renal function,
progression in ESRD patients was tested for an associa-incidence of proteinuria or diabetes among the different
tion with the underlying renal disease, no effect of thegenotype subgroups. The genotype of the three genes
ADD genotype on the rate of progression of any givenstudied was analyzed for an association with the suscepti-
cause of nephropathy could be identified. The time frombility to renal diseases. The expected frequencies of the
diagnosis to the onset of ESRD was previously reportedADD, AGT and ACE genotypes, under the assumption
to be shorter in the presence of the ACE-DD, than withof the Hardy-Weinberg equilibrium, did not differ from
DI or II genotypes [20]. The association of progressionobserved frequencies in ESRD patients and control sub-
of renal failure with the ACE I/D polymorphism wasjects. Comparison of biallelic frequencies alone or com-
particularly strong, when the interaction with the ADDbined in controls and ESRD patients is shown in Table 3.
genotype was analyzed, with a rapid progression inBiallelic pairs are shown for the combinations that are
ACE-DD (N  29) as compared to ACE-DI (N  95)supposed to protect against or predispose to high BP as
and II (N  43) in patients with the ADD-GG genotypedescribed above. Since the combined prevalence of ho-
(F-ratio 4.256; P 0.02, Fig. 2). No significant associa-mozygosity for these polymorphisms was low, data for the
tion was found between ADD and AGT genotype andfrequencies in the subgroups (healthy subjects, patients
progression of renal failure among all ESRD patients.with hypertension, on dialysis or with a transplant) are
In the population of healthy controls no relation be-not shown. The large majority of subjects (65.8%) were
tween either systolic or diastolic BP and the ADD geno-ADD GG homozygotes, while GW heterozygotes repre-
type was found, although in subjects with the ADD-Wsented 30.6% and WW homozygotes only 3.6%. There
allele (N 85) the BP was 144/86 21/13 mm Hg, whilewere no differences in the ADD genotype frequencies
in subjects with the GG genotype (N  171) the BPbetween controls and patients with ESRD.
averaged 139/84  22/13 mm Hg and the prevalence ofGenetic polymorphisms were analyzed for their rela-
the ADD-W allele tended to be higher in patients withtion to the rate of progression of renal disease and to
hypertension than in healthy controls (20.4 vs. 15.9%,BP or the presence or absence of hypertension. The time
P  0.08). A general linear model analysis of the effectfrom diagnosis to the onset of ESRD tended to be shorter
in the presence of the ADD-460WW (N  10), than of the three gene polymorphisms on systolic or diastolic
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Fig. 2. Interaction between the ADD and ACE polymorphism on the
rate of loss of renal function for 163 ESRD patients homozygous forFig. 1. ADD genotype and rate of progression of renal disease in years
the ADD GG genotype (F-ratio  4.256; P  0.02; mean  SD).from the time of diagnosis to the onset of end-stage renal disease
(ESRD) in 260 patients on renal replacement therapy (F-ratio  2.71,
P  0.068; differences between the WW and other genotypes by
Kruskal-Wallis test; mean  SD).
with the W allele tended to progress faster. This also
suggests that the W allele of the ADD gene may play
an important role in modulating the rate of progressionBP did not reveal any context dependency among these
of renal diseases.gene polymorphisms and BP.
The distribution of the G460W-ADD genotype in the
present population was similar to the genotype frequen-
DISCUSSION cies previously reported in a large Italian and French
population of normal subjects and hypertensive patientsThe findings of the present study indicate that the rate
[12], but differed sligthly from the allele frequencies re-of progression of renal diseases, as measured by the
ported in a population of patients with proteinuric ne-interval between the onset of renal disease to the onset
phropathy from the REIN study [25]. In this study onof ESRD, tends to be faster in patients homozygous for
212 prospectively evaluated patients with non-diabeticthe WW genotype in a homogeneous Caucasian popula-
proteinuric nephropathies, renal disease progression andtion of patients with nephropathies of various causes.
event rate (dialysis or transplantation) were found to beThus, it can be concluded that the ADD genotype plays
independent of the ADD genotype [25]. In the presenta role in modulating the progression, but not the onset,
population, patients with all causes of renal disease wereof renal diseases.
studied, including diabetes mellitus, interstitial nephritisCusi et al reported a positive association between the
or autosomal dominant polycystic kidney disease andoccurrence of hypertension and the ADD polymorphism
other non-proteinuric nephropathies. However, ADDin Italian and French populations, with hypertension be-
allele frequencies did not differ between patients withing associated with the presence of the W allele [12]. An
non-diabetic glomerulopathies as compared to patientsassociation between the ADD genotype and hyperten-
with nephropathies of other causes. Thus, taken togethersion was also found in one Japanese study [14], although
these findings support the view that the G460W-ADDthis association was not confirmed in other Japanese or
polymorphism may be relevant in modulating the rateAfrican American hypertensive patients [15, 16, 24]. In
of progression of renal diseases regardeless of the under-the studies where a positive association between the
lying cause.ADD polymorphism and hypertension was described,
This study has a number of limitations. Possible alter-patients with the GG genotype were compared to pa-
native explanations for the findings of genetic associationtients with the W allele [12, 14]. In the present study,
studies include linkage disequilibrium, population admix-however, when patients homozygous or heterozygous
ture [26] and the possibility of uncontrolled confoundingfor the W allele were compared to patients with the GG
factors. Genotyping for a well-studied ADD polymor-genotype no significant difference in the rate of progres-
sion of renal disease could be identifed, although subjects phism was performed, but it is possible that the actual
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causative locus may be represented by another ADD to protect from rapid progression to ESRD in ADD-GG
nucleotide variant or variants that are in linkage disequi- homozygotes (Fig. 2). This indicates that the described
librium with the 460W allele [27]. One potential uncon- effect of the ACE genotype on renal disease progression
trolled confounding factor relates to the effect of dietary [20] is enhanced in the presence of the GG, but disap-
salt in relation to the ADD genotype. Subjects with one pears on the background of the WW or WG-ADD geno-
or two copies of the variant 460W allele display high rates types. On the other hand, no effect of the interaction
of renal tubular sodium reabsorption [18]. The blood- between ADD and AGT phenotype was identified, while
pressure responses, both to diuretics and to infused sa- a positive interaction between the ACE polymorphism
line, are more pronounced in subjects with the variant and the AGT-MM genotype on the progression of renal
ADD allele than in those homozygous for the wild type disease was previously described [20].
[12, 28]. Thus, it is possible that the effect of the W allele In conclusion, susceptibility for ESRD is not linked
on the rate of renal function decline would be even with the ADD genotype. However, the ADD genotype
stronger when adjusted for the salt intake. Unfortu- is predictive of the course of renal function loss in an un-
nately, the design of the present study cannot evaluate selected renal population. Moreover, a variable progres-
the effects of dietary salt intake or the interaction of this sion to ESRD is associated with the ACE polymorphism
variability with the ADD polymorphism on the rate of on the background of the ADD-GG genotype. Thus,
progression of renal disease. Moreover, the phenotype the ADD gene may play a role in the understanding of
of salt-sensitivity, independent of blood pressure, has interindividual differences in the course of renal diseases.
been associated with an increased risk of cardiovascular
disease (CVD) events [29]. Since the ADD genotype ACKNOWLEDGMENTS
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